New NASH drug candidate BAR502 enters first human safety tests
NCT ID NCT06705998
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This early-phase study tests the safety and tolerability of a new drug called BAR502 in 52 healthy adults aged 18-55. Participants receive either a single or multiple doses of BAR502 or a placebo. The goal is to see how the body handles the drug and check for side effects before testing it in people with NASH (a liver condition).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CROSS Research S.A. Phase I Unit
RECRUITINGArzo, CH-6864, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.